CNBC·2025-11-03 23:40Core Viewpoint - Kimberly-Clark's acquisition of Kenvue, the maker of Tylenol, is expected to create shareholder value despite scrutiny surrounding Tylenol's safety claims [1][3]. Group 1: Acquisition Details - The acquisition deal is valued at $48.7 billion, aiming to form one of the largest consumer staple companies globally [3]. - Kenvue is known for other brands such as Neutrogena, Listerine, and Band-Aid, in addition to Tylenol [3]. Group 2: Market Reaction - Following the announcement of the acquisition, Kimberly-Clark's stock fell by 14.57%, while Kenvue's stock rose by over 12% [4]. Group 3: Sales Impact - Tylenol sales have experienced some impact due to claims linking acetaminophen to autism, but the effect is less significant than anticipated [2]. - The brand is described as resilient, with consumers continuing to respond positively to its effectiveness and safety [2][3].